Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Macular Edema - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Macular Edema - Pipeline Review, H2 2015', provides an overview of the Macular Edema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Macular Edema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Macular Edema Overview 7 Therapeutics Development 8 Pipeline Products for Macular Edema - Overview 8 Macular Edema - Therapeutics under Development by Companies 9 Macular Edema - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Macular Edema - Products under Development by Companies 13 Macular Edema - Companies Involved in Therapeutics Development 14 ActiveSite Pharmaceuticals, Inc. 14 Allergan Plc 15 Chong Kun Dang Pharmaceutical Corp. 16 Clearside BioMedical, Inc. 17 EyeGate Pharmaceuticals, Inc. 18 F. Hoffmann-La Roche Ltd. 19 Mabion SA 20 Pfizer Inc. 21 Promedior, Inc. 22 Taiwan Liposome Company, Ltd. 23 Xbrane Bioscience AB 24 Macular Edema - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 (triamcinolone acetonide + aflibercept) - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ASPPDC-020 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 beclomethasone dipropionate - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 celecoxib - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 dexamethasone acetate - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 dexamethasone acetate SR - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 PRM-167 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 ranibizumab - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ranibizumab biosimilar - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ranibizumab biosimilar - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ranibizumab biosimilar - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 triamcinolone acetonide - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Macular Edema - Recent Pipeline Updates 54 Macular Edema - Dormant Projects 63 Macular Edema - Discontinued Products 64 Macular Edema - Product Development Milestones 65 Featured News & Press Releases 65 Oct 12, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space Drug Administration 65 Jun 16, 2015: Clearside Biomedical Announces Favorable End-of-Phase 2 Review with the FDA 65 Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion 66 Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC's Ophthalmology Drug Phase I/II trial 67 Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 67 Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 67 Sep 24, 2013: Patent Approval granted by USPTO for TLC's BioSeizer Platform 69 May 21, 2013: Novartis's Ranibizumab Receives NICE Recommendation For Treatment Of Macular Edema 69 Apr 11, 2013: NICE Recommends Novartis's Ranibizumab For Treatment Of Macular Edema 70 Sep 05, 2012: New Data For Novartis Drug Lucentis Confirms Long-term Efficacy And Safety Profile And Benefits Of Individualized Treatment 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Macular Edema, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Comparative Analysis by Late Stage Development, H2 2015 10 Comparative Analysis by Clinical Stage Development, H2 2015 11 Comparative Analysis by Early Stage Development, H2 2015 12 Products under Development by Companies, H2 2015 13 Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015 14 Macular Edema - Pipeline by Allergan Plc, H2 2015 15 Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 16 Macular Edema - Pipeline by Clearside BioMedical, Inc., H2 2015 17 Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 18 Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 19 Macular Edema - Pipeline by Mabion SA, H2 2015 20 Macular Edema - Pipeline by Pfizer Inc., H2 2015 21 Macular Edema - Pipeline by Promedior, Inc., H2 2015 22 Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2015 23 Macular Edema - Pipeline by Xbrane Bioscience AB, H2 2015 24 Assessment by Monotherapy Products, H2 2015 25 Assessment by Combination Products, H2 2015 26 Number of Products by Stage and Target, H2 2015 28 Number of Products by Stage and Mechanism of Action, H2 2015 30 Number of Products by Stage and Route of Administration, H2 2015 32 Number of Products by Stage and Molecule Type, H2 2015 34 Macular Edema Therapeutics - Recent Pipeline Updates, H2 2015 54 Macular Edema - Dormant Projects, H2 2015 63 Macular Edema - Discontinued Products, H2 2015 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.